Evidence map›Paper›PMID 39885896›Full record

ArticleClinical and translational radiation oncology2024

Feasibility and safety of single-fraction sub-ablative radiotherapy with systemic therapy in colorectal cancer patients with ≤ 10 metastases: A multicenter pilot study (NCT05375708).

K Zwart, M N G J A Braat, F H van der Baan, A M May, J M L Roodhart, D Al-Toma, J M M B Otten, M Los, T Oostergo, R J A Fijneman and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

K ZwartDepartment of Medical Oncology, Imaging & Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
M N G J A BraatDepartment of Radiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
F H van der BaanDepartment of Medical Oncology, Imaging & Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
A M MayDepartment of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
J M L RoodhartDepartment of Medical Oncology, Imaging & Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
D Al-TomaDepartment of Medical Oncology, Imaging & Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
J M M B OttenDepartment of Oncology, Meander Medical Centre, Amersfoort, the Netherlands.
M LosDepartment of Oncology, St. Antonius, Nieuwegein, the Netherlands.
T OostergoDepartment of Oncology, Diakonessenhuis, Utrecht, the Netherlands.
R J A FijnemanDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
J M van Dodewaard-de JongDepartment of Oncology, Meander Medical Centre, Amersfoort, the Netherlands.
C J A PuntDepartment of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
G MeijerDepartment of Radiotherapy, Imaging & Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
J J W LagendijkDepartment of Radiotherapy, Imaging & Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
M KoopmanDepartment of Medical Oncology, Imaging & Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
M IntvenDepartment of Radiotherapy, Imaging & Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
G M BolDepartment of Medical Oncology, Imaging & Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer patients with ≤10 unresectable metastases were treated with single-fraction sub-ablative radiotherapy in addition to standard of care systemic therapy in a single-arm, open-label, multicenter, pilot study (SIRIUS) to assess feasibility and safety. Results indicate that radiotherapy combined with systemic therapy is feasible and safe in this population.

Indexed as

Oligometastasesphase ISBRTSingle fractionSystemic therapy

Identifiers

PMID39885896
PMCPMC11780375

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.